Katherine Cunha, NP

Dr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.

Dr. Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib.

Dr. Kim discusses her approach to selecting the next treatment for patients with ALK+ NSCLC who progress on lorlatinib, including the key factors she considers in making this decision.

Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.

Dr. Kim discusses her experience with lorlatinib in real-world settings for ALK+ NSCLC, highlighting both the benefits and challenges of incorporating it into clinical practice.

Dr. Garon describes the current treatment landscape for metastatic ALK+ NSCLC and explores alternative treatment options that could have been considered for these patients.

Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.

Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Dr. Garon discusses his approach to selecting between available EGFR inhibitors for treating EGFR+ NSCLC.

Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.

Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.

A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.

The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.